NZ597024A - Cardiovascular related uses of il-1beta antibodies and binding fragments thereof - Google Patents

Cardiovascular related uses of il-1beta antibodies and binding fragments thereof

Info

Publication number
NZ597024A
NZ597024A NZ597024A NZ59702410A NZ597024A NZ 597024 A NZ597024 A NZ 597024A NZ 597024 A NZ597024 A NZ 597024A NZ 59702410 A NZ59702410 A NZ 59702410A NZ 597024 A NZ597024 A NZ 597024A
Authority
NZ
New Zealand
Prior art keywords
subject
cardiovascular
cardiovascular event
binding fragments
related uses
Prior art date
Application number
NZ597024A
Other languages
English (en)
Inventor
Patrick J Scannon
Jeffrey D Feldstein
Alan M Solinger
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Publication of NZ597024A publication Critical patent/NZ597024A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ597024A 2009-05-29 2010-05-28 Cardiovascular related uses of il-1beta antibodies and binding fragments thereof NZ597024A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18267909P 2009-05-29 2009-05-29
US25257109P 2009-10-16 2009-10-16
US31300110P 2010-03-11 2010-03-11
PCT/US2010/036761 WO2010138939A1 (en) 2009-05-29 2010-05-28 CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF

Publications (1)

Publication Number Publication Date
NZ597024A true NZ597024A (en) 2014-01-31

Family

ID=43223130

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597024A NZ597024A (en) 2009-05-29 2010-05-28 Cardiovascular related uses of il-1beta antibodies and binding fragments thereof

Country Status (15)

Country Link
US (3) US20100316651A1 (enExample)
EP (1) EP2435073A4 (enExample)
JP (2) JP5763625B2 (enExample)
KR (1) KR20120061041A (enExample)
CN (2) CN107243077A (enExample)
AU (1) AU2010253924B2 (enExample)
BR (1) BRPI1011228A2 (enExample)
CA (1) CA2763161A1 (enExample)
EA (1) EA201101643A1 (enExample)
HK (1) HK1245111A1 (enExample)
IL (1) IL216660A0 (enExample)
MX (1) MX2011012666A (enExample)
NZ (1) NZ597024A (enExample)
SG (3) SG10201500180RA (enExample)
WO (1) WO2010138939A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013025368A8 (pt) * 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
PL2623604T3 (pl) * 2012-02-02 2015-07-31 Baylor College Medicine Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
EP4628162A3 (en) * 2012-10-04 2025-12-03 XBiotech Inc. Treating vascular disease and complications thereof
US10000565B2 (en) 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
US10000557B2 (en) * 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
CN103059136A (zh) * 2012-12-24 2013-04-24 浙江大学 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
CN113874034A (zh) * 2019-05-03 2021-12-31 苏黎世大学 脑缺血再灌注损伤的治疗
US20220275079A1 (en) * 2020-11-20 2022-09-01 The General Hospital Corporation Clonal Hematopoiesis and Risk of Chronic Liver Disease
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820383B2 (en) * 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
CN101228188A (zh) * 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
JP4524275B2 (ja) * 2006-09-01 2010-08-11 日本ポリプロ株式会社 ビニル基および極性基含有プロピレン系共重合体及びそれを用いる重合体の製造方法。
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases

Also Published As

Publication number Publication date
HK1245111A1 (zh) 2018-08-24
AU2010253924B2 (en) 2015-01-22
WO2010138939A1 (en) 2010-12-02
US20100316651A1 (en) 2010-12-16
CA2763161A1 (en) 2010-12-02
KR20120061041A (ko) 2012-06-12
EP2435073A4 (en) 2013-03-27
SG176265A1 (en) 2012-01-30
AU2010253924A1 (en) 2012-01-19
BRPI1011228A2 (pt) 2019-09-24
JP2015120704A (ja) 2015-07-02
US20180155420A1 (en) 2018-06-07
SG2014014534A (en) 2014-07-30
SG10201500180RA (en) 2015-03-30
CN107243077A (zh) 2017-10-13
JP2012528796A (ja) 2012-11-15
EP2435073A1 (en) 2012-04-04
US20210009679A1 (en) 2021-01-14
MX2011012666A (es) 2011-12-16
IL216660A0 (en) 2012-02-29
EA201101643A1 (ru) 2012-12-28
JP5763625B2 (ja) 2015-08-12
CN102573893A (zh) 2012-07-11
US10611832B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
NZ597024A (en) Cardiovascular related uses of il-1beta antibodies and binding fragments thereof
Lonardo et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome
You et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
NI201000034A (es) Activadores de guanilato ciclasas solubles.
RU2014132591A (ru) Титановые сплавы
JP2013501166A5 (enExample)
WO2010049678A3 (en) Treatment of energy utilization diseases
JP2011500690A5 (enExample)
BR112013032375A2 (pt) conjugado compreendendo oxintomodulina e um fragmento de imunoglobulina, e seus usos
NZ588623A (en) Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization
DE602007001036D1 (de) Abgepacktes Konzentrat zur Zubereitung von Bouillon, Suppe, Sauce, Tunke oder zur Verwendung als Würze sowie das Konzentrat mit modifizierter Stärke
WO2009057664A1 (ja) 抗体及びその利用
Bockeria et al. Statin therapy in the primary prevention of early atrial fibrillation after coronary artery bypass grafting
JP2007510403A5 (enExample)
PH12015502100A1 (en) Reducing the risk of autoimmune disease
GT200500266A (es) Nuevos derivados de pirimidina y su uso
AR056484A1 (es) PANEL QUE CONTIENE BAMBu
PL399962A1 (pl) Zastosowanie oleaceiny, zwlaszcza z Ligustrum vulgare L.
WO2015175502A3 (en) Replacement therapy for natriuretic peptide deficiencies
WO2015039036A3 (en) Novel cytochrome p450 inhibitors and their method of use
EP2484692A4 (en) MIMETIC APOLIPOPROTEIN A-1-PEPTIDES AND THERAPEUTICS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA THEREWITH
Heilbron et al. Management of atrial fibrillation in the emergency department and following acute myocardial infarction.
Jang et al. A Case of Pheochromocytoma Presenting as Stress-Induced Cardiomyopathy with Large Left Ventricular Thrombus
Antz et al. Oral anticoagulation for atrial fibrillation
Kryuchkova et al. Effectiveness of perindopril and amlodipine combination in hypertensives with COPD

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 MAY 2017 BY SHELSTON IP

Effective date: 20140502

ASS Change of ownership

Owner name: XOMA (US) LLC, US

Effective date: 20150730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2018 BY COMPUTER PACKAGES INC

Effective date: 20170502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2019 BY COMPUTER PACKAGES INC

Effective date: 20180501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20190501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210430

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2023 BY COMPUTER PACKAGES INC

Effective date: 20220430

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230430

LAPS Patent lapsed